




<b>(51) International Patent Classification 5 :</b> <b>A61K 47/48, C07D 305/14</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/00156</b>
<b>(21) International Application Number:</b> <b>PCT/EP93/01433</b>			<b>(43) International Publication Date:</b> <b>6 January 1994 (06.01.94)</b>
<b>(22) International Filing Date:</b> <b>7 June 1993 (07.06.93)</b>			<b>(74) Agent:</b> <b>FERRARIO, Vittorino; R.S./Documentation and Patent Department, Farmitalia Carlo Erba S.r.l., Via Carlo Imbonati, 24, I-20159 Milan (IT).</b>
<b>(30) Priority data:</b> 9213077.2 19 June 1992 (19.06.92) GB			<b>(81) Designated States:</b> <b>AU, BY, CA, CZ, FI, HU, JP, KR, KZ, NO, NZ, PL, RU, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b>
<b>(71) Applicant:</b> <b>FARMITALIA CARLO ERBA S.R.L. [IT/IT]; Via Carlo Imbonati, 24, I-20159 Milan (IT).</b>		<b>Published</b>	<i>With international search report.</i>
<b>(72) Inventors:</b> <b>MONGELLI, Nicola ; Via Tertulliano, 38, I-20137 Milan (IT). ANGELUCCI, Francesco ; Via G. Washington, 106, I-20146 Milan (IT). PESENTI, Enrico ; Viale Visconti, 9, I-20093 Cologno Monzese (IT). SARATO, Antonio ; Via Degli Imbriani, 39, I-20158 Milan (IT). BIASOLI, Giovanni ; Via Scalarini, 31, I-21046 Gavirate (IT).</b>			

**(54) Title: POLYMER-BOUND PACLITAXEL DERIVATIVES**



### (57) Abstract

A polymer conjugate consisting essentially of: from 90 to 99.9 mol % of units represented by formula (a); from 0.1 to 5 mol % of units represented by formula (b), wherein one of  $R_1$  and  $R_2$  is a copolymer residue of formula (c), and the other one is hydrogen atom; from 0 to 9.9 mol % of units represented by formula (d), wherein R is a phenyl or t-butoxy group,  $R_3$  is H or an acetyl group, A and  $A_1$  which may be the same or different, represent a chemical single bond, an amino acid residue or peptide spacer selected from  $\beta$  Ala, Gly, Phe-Gly, Phe-Phe-, Leu-Gly, Val-Ala, Phe-Ala, Leu-Phe, Leu-Ala, Phe-Leu-Gly, Phe-Phe-Leu, Leu-Leu-Gly, Phe-Tyr-Ala, Phe-Gly-Phe, Phe-Phe-Gly, Phe-Leu-Gly-Phe, Gly-Phe-Leu-Gly-Phe, Gly- $\beta$ Ala, Phe-Gly- $\beta$ Ala, Phe-Phe- $\beta$ Ala, Leu-Gly- $\beta$ Ala, Val-Ala- $\beta$ Ala, Phe-Ala- $\beta$ Ala, Leu-Phe- $\beta$ Ala, Leu-Gly- $\beta$ Ala, Phe-Leu-Gly- $\beta$ Ala, Phe-Phe-Leu- $\beta$ Ala, Leu-Leu-Gly- $\beta$ Ala, Phe-Tyr-Ala- $\beta$ Ala, Phe-Gly-Phe- $\beta$ , Phe-Phe-Gly- $\beta$ Ala, Phe-Leu-Gly-Phe- $\beta$ Ala or Gly-Phe-Leu-Gly-Phe- $\beta$ Ala. The compounds are endowed with antitumor activity and show improved water solubility and decreased toxicity in comparison with paclitaxel or its known analogs. A method for their preparation and pharmaceutical compositions containing them are also described.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				


- 1 -

#### POLYMER-BOUND PACLITAXEL DERIVATIVES

The present invention is directed to polymer-bound paclitaxel and polymer-bound paclitaxel derivatives endowed with antitumor activity, to a method for their preparation and to pharmaceutical compositions containing them.


Paclitaxel (also named Taxol in several publications) is a member of the taxane family of diterpenes, isolated and characterized from an extract of bark of Taxus brevifolia L.; other analogues of paclitaxel are also known and were prepared by semisynthesis starting from 10-deacetyl baccatin III, extracted from the needles of Taxus baccata L., see Wain et al. in JACS, 93, 2325 (1971) and Lovelle et al., Proc. Am. Assoc. Cancer Res., 31, p. 417, (1990). These compounds have been shown to possess potent antitumor activity, but they are very slightly soluble in water and some toxic side-effects are associated also with their administration by injection or intravenous infusion using as carrier cremophor EL (TM). The present invention provides a polymer conjugate of the formula I consisting essentially of:

from 90 to 99.9 mol % of units of the formula:




from 0.1 to 5 mol % units represented by the formula

- 2 -




wherein one of  $R_1$  and  $R_2$  is a copolymer residue of the formula



5 and the other one is hydrogen atom;

from 0 to 9.9 mol % of units represented by the formula



wherein R is a phenyl or t-butoxy group,  $R_3$  is H or an 10 acetyl group, A and  $A_1$  which may be the same or different, represent a chemical single bond, an amino acid residue or peptide spacer selected from  $\beta$  Ala, Gly, Phe-Gly, Phe-Phe-, Leu-Gly, Val-Ala, Phe-Ala, Leu-Phe, Leu-Ala, Phe-Leu-Gly, Phe-Phe-Leu, Leu-Leu-Gly, Phe-Tyr-Ala, Phe-Gly-Phe, Phe-Phe-Gly, Phe-Leu-Gly-Phe, Gly-Phe-Leu-Gly-Phe, Gly- $\beta$ Ala, Phe-Gly- $\beta$ Ala, Phe-Phe- $\beta$ Ala,

- 3 -

Leu-Gly- $\beta$ Ala, Val-Ala- $\beta$ Ala, Phe-Ala- $\beta$ Ala, Leu-Phe- $\beta$ Ala,  
Leu-Gly- $\beta$ Ala, Phe-Leu-Gly- $\beta$ Ala, Phe-Phe-Leu  $\beta$ Ala, Leu-  
Leu-Gly- $\beta$ Ala, Phe-Tyr-Ala- $\beta$ Ala, Phe-Gly-Phe- $\beta$ , Phe-Phe-  
Gly- $\beta$ Ala, Phe-Leu-Gly-Phe- $\beta$ Ala or Gly-Phe-Leu-Gly-Phe-  
5  $\beta$ Ala.

More particularly the present invention provides polymer conjugates of paclitaxel and derivatives of paclitaxel with improved water solubility and decreased toxicity.

Preferably, the mol % of units containing the paclitaxel  
10 and paclitaxel derivatives is from 0.5 to 2, more  
preferably, the content of paclitaxel in the polymer was  
from 2 to 10 % (w/w), most preferred compounds are those  
characterized by a content of from 4 to 7 % (w/w). The  
wavy line denotes that the oxygen linked at position 7 of  
15 the paclitaxel structure may be in both configurations,  
i.e.  $\beta$  (natural) or  $\alpha$ .

Preferably R represents a phenyl group, R<sub>3</sub> is an acetyl group and A is a Phe-Leu-Gly or Phe-Leu-Gly- $\beta$ Ala residue.

All the amino acid residues have the natural L-  
20 configuration. According to a preferred embodiment, the  
polymer conjugate is a copolymer of 1-methacryloylamino-  
2-hydroxypropane, (methacryloylglycyl-phenylalanyl-  
leucylglycyl)3-amino-2 hydroxypropane and 2'-  
(methacryloylglycylphenylalanylleucylglycyl- $\beta$ alanyl)  
25 paclitaxel.

The % w/w content was determined after enzymatic hydrolysis by HPLC method analogous to that described in Cancer Treatment Rep. 71 (1), 1987, p. 53-59.

- 4 -

Enzymatic hydrolysis

To 1 ml of murine or human plasmas various concentrations of the polymer-bound paclitaxel were added and at appropriate time (24, 48, 72, 96 h) 100  $\mu$ l were collected  
5 and stored at -70°C until further processing.

Extraction procedure


Samples were extracted by adding 75  $\mu$ l of Tetra Butyl Ammonium Phosphate (TBAP) 0.5 M, 1250  $\mu$ l CH<sub>3</sub>CN and 150  $\mu$ l of NaCl 5M and vigorously shacked for 20' at 4°C.  
10 After that time samples were spun at 15000 x g for 10' and the supernatants were collected and evaporated using a high vacuum centrifuge . Samples were recovered by adding 500  $\mu$ l of MeOH:H<sub>2</sub>O (75:25 V/V) and injected into HPLC for determining the total paclitaxel percentage  
15 content.

HPLC system


Column : Nova Pak C<sub>18</sub> (Waters) 3.9 x 300 mm  
Flow Rate : 1.5 ml/m  
Detector : UV 231 nm  
20 Injection : 20  $\mu$ l  
Mobile Phase : 57.5 % H<sub>2</sub>O brought to pH 2  
42.5 % CH<sub>3</sub>CN

The present invention also provides a process for preparing a polymer conjugate which process comprises  
25 reacting a compound of the formula II


- 5 -



wherein one of  $A_2$  and  $A_3$  is a chemical bond and the other one is  $A$ , and  $A$ ,  $R$  and  $R_3$  are as defined above, with an activated polymer consisting essentially of from 90 to 99.9 mol % of units represented by formula



and from 10 to 0.1 mol % of units represented by the formula



wherein A<sub>1</sub> is as defined above and then treating the resultant polymer conjugate with 2-hydroxypropylamine.

Preferably the reaction between the compounds of the formula II and the activated polymer is carried out in

15 an anhydrous polar organic solvent such as dimethylsulfoxide or dimethylformamide optionally in presence of an organic or inorganic base such as an alkaline carbonate, dimethylaminopyridine or

- 6 -

triethylamine. The reaction can typically be effected for from 1 to 24 hours.

The reaction is typically carried out at a temperature of from 15 to 40°C, preferably at room temperature. The 5 alkaline carbonate is, for example, an alkali metal carbonate or an alkaline earth metal carbonate.

Some of the starting compounds of the formula II are known compounds, i.e. paclitaxel or paclitaxel analogues or may be prepared starting from known compounds.

10 For example 7-epi derivatives may be prepared by refluxing in toluene paclitaxel or its analogs in the presence of a base (Na<sub>2</sub>CO<sub>3</sub> or diazabicycloundecene)

Other compounds of the formula II are new, in particular those in which A<sub>3</sub> is  $\beta$ Ala residue and those in which 15 either A<sub>2</sub> or A<sub>3</sub> represents di, tri, or tetra peptide spacer as defined above for A and are within the scope of the invention.

The compounds of formula II wherein A<sub>2</sub> is not a chemical single bond may be prepared by reacting a paclitaxel or a 20 paclitaxel analog with protected amino acid or peptide in the presence of a condensating reagent, and with or without the additional presence of a catalyst, preferably at room temperature, followed by the removal of the protecting group with known methods.

25 The condensation may be also carried out using activated esters such as paranitrophenyl ester of peptide or amino acid. Suitable condensing reagents include carbodiimides such as dicyclohexyl carbodiimide (DCC).

- 7 -

Suitable catalysts include 4-dimethylamino-pyridine (DMAP), pyridine or triethylamine.

Various known amino protecting groups can be utilized and commercially available protected amino acid or peptides can be utilized as the starting materials. Amino acids or peptides protected with t-BOC, trityl, FMOC or carbobenzyloxy (CBZ) can be utilized. Amino Acid or peptides procted with t-BOC, trityl or FMOC groups are preferred.

10 The compounds of the formula II wherein A<sub>3</sub> is not a chemical single bond may be prepared by protecting or blocking the 2'-hydroxy group and then esterifying the 7-position hydroxyl and then removing the 2'-protecting or blocking group.

15 More preferably, the compounds of the formula II wherein A<sub>3</sub> is Gly or  $\beta$ Ala residue are prepared by reacting paclitaxel with 2-3 equivalents of N-protected amino acid to produce 2',7-disubstituted paclitaxel, the 2'-position amino acid is cleaved and then the 7-position amino acid 20 is deprotected.

Reaction of paclitaxel and the protected amino acid is conducted in the presence of a condensing reagent and a catalyst, like those above defined.

25 Cleavage of the 2'-amino acid is conducted by adjusting the pH of the 2'-7-(amino acid) paclitaxel solution to pH 7-7.4 for example by mixture of the 2',7-di(amino acid) paclitaxel in a phosphate buffer at pH 7-7.4 or with a slight excess of NaHCO<sub>3</sub>.

- 8 -

Deprotection of the amino acid is conducted under a known amino acid deprotection method, such as mild acid treatment with, for example, acetic acid, or by reduction.

5 Thus, for example, paclitaxel is allowed to react with 2-3 mol. equivalent of N-protected amino acid (t.boc, CBZ or FMOC protected) in methylene chloride in the presence of DCC and a catalytic amount of 4-dimethylaminopyridine. In this manner, the protected amino acid is introduced at 10 2' and 7-position. The 2',7-bis amino acid derivative of paclitaxel is allowed to stand in presence of  $\text{NaHCO}_3$  in  $\text{H}_2\text{O}/\text{MeOH}$  for 2-5 hours, whereby selective deprotection at the 2'-position occurs to yield the 7-substituted derivative of paclitaxel. The protecting groups are 15 removed by appropriate deprotecting agent (e.g., acid, mild base or hydrogenolysis).

The activated polymer is a synthetic, water soluble polymer prepared by the copolymerization of N'-(2-hydroxypropyl) methacrylamide with p-nitrophenylesters 20 of N-methacryloyl oligopeptides, as described in US-A-4062831 and US-A-4097470.

The polymer conjugates of the formula I and the new paclitaxel derivatives of the formula II exhibit good water solubility, biocompatibility and release the 25 paclitaxel or paclitaxel derivative in the plasma or after internalization into cells by cleaving of the oligopeptide spacers.

- 9 -

Biological activity

Microtubule assembly and disassembly assay

Calf brain tubulin was prepared by two cycles of assembly-disassembly (Shelanski M.L. Gaskin F. and Cantor C.R., Proc. Natl. Acad. Sci. U.S.A. 70, 765-768, 1973) and stored in liquid nitrogen in MAB (0.1 M MES, 2.5 mM EGTA, 0.5 mM MgSO<sub>4</sub>, 0.1 mM EDTA, 0.1 mM DTT pH 6.4).

All the experiments were carried out on protein stored for less than 4 weeks.

Before each experiment, the tubulin was kept 30 min at 4 °C.

Assembly was monitored by the method of Gaskin et al (Gaskin F., Cantor C.R. Shelanski M.L. J. Molec. Biol 89, 737-758, 1974). The cuvette (1 cm path) containing tubulin (1 mg/ml) and 1 mM GTP was shifted to 37°C and continuous turbidity measurements were made at 340 nm on Perkin-Elmer 557 Double Wavelength Double Beam Spectrophotometer equipped with an automatic recorder and a thermostatically regulated sample chamber.

After 30 minutes 4 mM CaCl<sub>2</sub> was added and depolymerisation was measured for 10 minutes as decreased turbidity. At regular intervals of 15 minutes scalar doses of the tested compounds were added and variations in the turbidity were monitored. Data are expressed as percentage of ripolymerisation induced by the tested compounds. The results are shown in Table I.

- 10 -

In vitro drug sensitivity assay

Exponentially growing B16-F10 murine melanoma cells were seeded ( $2 \times 10^4/\text{ml}$ ) in RPMI 1640 medium were supplemented with 10% heat-inactivated fetal calf serum and 2 mM glutamine in 24 well-plates (Costar). Scalar concentrations of tested compounds were added immediately after seeding. The inhibition of cell growth was evaluated by counting cells with a coulter counter after 72 hrs incubation. For each tested compound concentration triplicate cultures were used. The antiproliferative activity of the tested compounds was calculated from dose-response curves and expressed as  $\text{IC}_{50}$  (dose causing 50% inhibition cell growth in treated cultures relative to untreated controls). The result are shown in Table I.

15

Table I

20

Compound prepared in	Tubulin Assembly %		$\text{IC}_{50}$ ( $\mu\text{M}$ )
	0.5 $\mu\text{M}$	5 $\mu\text{M}$	
Example 1	0	15	19
Example 9	79	145	47
Example 3	46	86	23
Example 4	0	10	11
Example 6	0	10	51
Reference compound : Paclitaxel	41	96	39

- 11 -

The copolymer-paclitaxel prepared in Example 6 was tested in vivo against B16 F10 murine melanoma in comparison with paclitaxel.

Mice

5 C57B16 female mice were obtained from Charles River Italy.

Animals were 8 to 10 weeks old at the beginning of the experiment.

Drugs

10 Because of its limited aqueous solubility, paclitaxel was dissolved in a vehicle consisting of polyoxyethylated castor oil (Cremophor EL) 50% and ethanol 50% and then diluted with glucose 5% solution at the desidered concentrations. The solution was slightly hazy and 15 precipitates formation was observed after short time.

The compound of example 6 was easily dissolved in glucose 5% and the resulting solution was clear for long time (more than 2 hours). Final concentrations were referred to the paclitaxel content of the compound (4% of total).

20 Tumor

The murine melanoma B16F10 was used. A suspension of  $10^5$  tumor cells in 0.2 ml was injected subcutaneously in the flank of mice.

25 Tumor size was measured with caliper and tumor weight was calculated with the formula:

$$\frac{a^2+b}{2}$$

- 12 -

Drugs administration

Paclitaxel was given intraperitoneally because of its poor solubility and vehicle toxicity.

The compound of example 6 was injected intravenously.

5 Both compounds were administered at day 1, 5, 9 after tumor implantation.

The data reported in Table 2 show that the compound of the present invention is more active than paclitaxel.

10 The dose of the polymer-conjugate is referred to the paclitaxel content.

Table 2

Compound	Dose (mg/Kg)	Tumor Inhibition (%)	Tox
Control	-	-	-
Paclitaxel	14.6	53	0/10
	22	38	0/10
	33	92	1/7
15 Compound of ex. 6	14.6	77	0/9
	22	79	0/10

TOX: number of mice which died for toxicity.

TOX determination was made when mice died before the control or when significant body weight loss and/or spleen and or/or liver size reduction were observed.

20 From the above data, it can be seen that the polymer

- 13 -

conjugates of the present invention exhibit excellent antitumor activity. These compounds, therefore, are useful antitumor agents due to the lower toxicity and increased water solubility as compared to paclitaxel or 5 its derivative. Examples of tumors that can be treated are for instance, sarcomas, carcinoma, lymphomas, neuroblastoma, melanoma, myeloma, Wilms tumor, leukemias and adenocarcinoma.

The improved solubility and decreased toxicity of the 10 polymer-conjugates of the present invention means that they are suitable for intravenous injection or infusion. The dosage depends upon the age, weight and condition of the patient. The dosage may be from 1 mg/kg body weight to 1 g/kg body weight, preferably from 4 to 800 mg/kg 15 body weight. Typical formulations contain a quantity of polymer-bound paclitaxel/polymerbound paclitaxel derivative equivalent to 0.5, 1.5, 10, 20, 25, or 50 mg of the active paclitaxel/paclitaxel derivative.

The polymer conjugates may be formulated as 20 pharmaceutical compositions with a pharmaceutically acceptable carrier or diluent. Any appropriate carrier or diluent may be used. The solutions for intravenous injection or infusion may contain as carrier or diluent, for example, sterile water or preferably they may be in 25 the form of sterile, aqueous or isotonic saline solutions.

The following examples illustrate the invention.

- 14 -

Example 1

Copolymer of 1-methacryloylamino-2-hydroxypropane,  
1 (methacryloyl-glycyl-phenylalanyl-leucyl-glycyl)amino-  
2-hydroxypropane and 2' (methacryloyl-glycyl-phenyl -  
5 alanyl-leucyl-glycyl) paclitaxel.

To a solution of 1.4 g of copolymer of 1-methacryloyl-  
amino-2-hydroxypropane and N-(methylencarbonyl-Phe- Leu-  
Gly 4-nitrophenoxy)methacrylamide, prepared according to  
J. Kopecek et al., Makromol Chem 177, p. 2833 (1976), in  
10 15 ml of anhydrous dimethylformamide were added 100 mg of  
paclitaxel and 15 mg of dimethylaminopyridine.

The yellow solution was stirred for 8 hours at room  
temperature under anhydrous conditions. Then 2-hydroxy  
propylamine (0.2 ml) was dropped into reaction flask, and  
15 then the whole was stirred for 30 minutes.

The reaction solution was quenched with 0.3 ml glacial  
acetic acid, concentrated under vacuum to a small volume,  
and then poured into 200 ml of acetone.

After 30' mixing, the precipitate was filtered and washed  
20 with acetone to yield 1.25 g of the title compound.

The paclitaxel content was 4.5% (evaluated by enzymatic  
hydrolysis and HPLC analysis).

Unreacted paclitaxel was recovered from acetone solution.

Example 2

2' (N-trityl-phenylalanyl-leucyl-glycyl) paclitaxel

To a solution of 170 mg of paclitaxel in 16 ml of  
acetonitrile were added 24 mg of dimethylamino-pyridine  
and 150 mg of N-trityl-phenylalanyl-leucyl-glycine 4-

- 15 -

nitrophenyl ester.

The yellow solution was stirred for 20 hours at room temperature, and then evaporated under vacuum to dryness. The residue was chromatographed on silica gel with ethyl-acetate-hexane 35:25 as eluant, affording 380 mg of the title compound.

<sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : δ

0.82 (d, J=6.4 Hz, 3H, δ-Leu)  
0.85 (d, J=6.7 Hz, 3H, δ-Leu)  
10 1.15 (s, 3H, 16)  
1.26 (s, 3H, 17)  
1.2-1.6 (m, 3H, β+β+γ-Leu)  
1.69 (s, 3H, 19)  
1.85 (s, 1H, OH-1)  
15 1.89 (m, 1H, 6β)  
1.96 (d, J=1.2 Hz, 3H, 18)  
2.14 (dd, J=5.9 Hz, J=13.5 Hz, 1H, β-Phe)  
2.24 (s, 3H, CH<sub>3</sub>CO-10)  
2.2-2.7 (m, 5H, CH<sub>2</sub>-14+OH-7+6α+βPhe+NH-Phe)  
20 2.47 (s, 3H, CH<sub>3</sub>CO-4)  
3.50 (m, 1H, α-Phe)  
3.74 (dd, J=4.7 Hz, J=18.2 Hz, 1H, α-Gly)  
3.80 (m, 1H, α-Leu)  
3.83 (d, J=7.0 Hz, 1H, 3)  
25 4.17 (dd, J=7.0 Hz, J=18.2 Hz, 1H, α'-Gly)  
4.22, 4.33 (two-d, J=8.5 Hz, 2H, CH<sub>2</sub>-20)  
4.46 (m, 1H, 7)  
4.97 (dd, J=2.2 Hz, J=9.9 Hz, 1H, 5)

- 16 -

5.44 (d, J=2.3 Hz, 1H, 2')  
5.71 (d, J=7.0 Hz, 1H, 2)  
5.97 (dd, J=4.7 Hz, J=7.0 Hz, 1H, NH-Gly)  
6.07 (dd, J=2.3 Hz, J=9.4 Hz, 1H, 3')  
5 6.2-6.3 (m. 2H, 13+10)  
6.8-9.2 (m, 30 H, 6- Ph)  
6.95 (d, J=6.7 Hz, 1H, NH-Leu)  
8.00 (d, J=9.4 Hz, 1H, NH-4')

Example 3

10 2' (phenylalanyl-leucyl-glycyl) paclitaxel.

The compound 2' (N-Trit-Phe-Leu-Gly) paclitaxel (250 mg) was dissolved into a mixture of glacial acetic (22 ml) and water (6 ml) and the whole was stirred for 1 hour at room temperature.

15 The solvents were evaporated in vacuum to the dryness, the residue stirred with diethylether-hexane 1:1 for 30 minutes and filtered to obtain 160 mg of the title compound.

FAB-MS: m/z 1171, M+H]<sup>+</sup>; 1112, M-CH<sub>3</sub>COOH + 2H; 1051, 20 1024, 911, 603, 569, 509.

<sup>1</sup>H-NMR (400MHz, CDCl<sub>3</sub>): δ

0.88 (d, J=6.4Hz, 3H, δ Leu)  
0.92 (d, J=6.4Hz, 3H, δ' Leu)  
1.13 (s, 3H, 16)  
25 1.16 (s, 3H, 17)  
1.4-2.0 (m, 4H, β+β'+γLeu+6β)  
1.69 (s, 3H, 19)  
1.91 (d, J=1.2Hz, 3H, 18)

- 17 -

2.16 (dd, J=6.0 Hz, J=13.8Hz, 1H, 14)

2.23 (s, 3H, COCH<sub>3</sub>-10)

2.4-2.6 (m, 3H, 6 $\alpha$ +14+ $\beta$ Phe)

2.53 (s, 3H, COCH<sub>3</sub>-4)

5 2.90 (dd, J=4.1Hz, J=13.5Hz, 1H,  $\beta'$ -Phe)

3.49 (dd, J=4.1 Hz, J=9.1Hz, 1H,  $\alpha$ Phe)

3.82 (d, J=7.3Hz, 1H, 3)

3.9-4.1 (m, 2H,  $\alpha$ + $\alpha'$ Gly)

4.22, 4.33 (two-d, J=8.7 Hz, 2H, CH<sub>2</sub>-20)

10 4.27 (m, 1H,  $\alpha$ -Leu)

4.44 (dd, J=6.4Hz, J=10.8Hz, 7)

4.98 (dd, J=2.4Hz, J=9.7 Hz, 5)

5.61 (d, J=3.2Hz, 1H, 2')

5.70 (d, J=7.3Hz, 1H, 2)

15 6.12 (dd, J=3.2Hz, J=9.4Hz, 1H, 3')

6.21 (m, 1H, 13)

6.28 (s, 1H, 10)

6.8-8.2 (m, 21H, 4-Ph + NHLeu)

7.87 (d, J=9.4Hz, 1H, NH-4')

20 Example 4

Copolymer of 1-methacryloylamino-2-hydroxypropane, 1-(methacryloyl-glycyl)amino-2-hydroxypropane and 2'-(methacryloyl-glycyl-phenylalanyl-leucyl-glycyl)paclitaxel.

25 To a solution of 1 g of copolymer of 1-methacryloylamino-2-hydroxypropane and N-(methylencarbonyl-4-nitro- phenoxy)methacrylamide, prepared according to P. Rejmanova et al., Makromol. Chem. 178, p. 2159-2168, in

- 18 -

10 ml of anhydro dimethylformamide were added 100 mg of 2' Phe-Leu-Gly-paclitaxel and 10 mg of dimethylaminopyridine.

The yellow solution was stirred for 2 hours at room 5 temperature under anhydrous conditions. Then 2-hydroxy - propylamine (0.15 ml) was added to the reaction solution, and the whole was stirred for 30 minutes. The reaction solution was quenched with 0.2 ml of glacial acetic acid, concentrated under vacuum to a small volume and then 10 poured into 200 ml of acetone.

The mixture was stirred for 1 hours, the precipitate was filtered and washed with acetone to yield 960 mg of the title compound.

The paclitaxel content was 6% (evaluated by enzymatic 15 hydrolysis and HPLC analysis).

Example 5

Copolymer of 1-methacryloylamino-2-hydroxy -propane, 1(methacryloyl-glycyl)amino-2-hydroxypropane and 2'(methacryloyl-glycyl)paclitaxel.

20 To a solution of 1.6 g of copolymer of 1-methacryloyl - amino-2-hydroxypropane and N-(methylen-carbonyl-4-nitro- phenoxy)methacrylamide in 16 ml of anhydrous dimethyl- formamide were added 100 mg of paclitaxel and 20 mg of dimethylamino-pyridine. The yellow solution was stirred 25 for 20 hours at room temperature, then 2- hydroxypropylamine (0.2 ml) was added, and the whole was stirred for 30 minutes. The reaction solution was quenched with 0.3 ml of glacial acetic acid, concentrated

- 19 -

under vacuum to a small volume, and then poured into 200 ml of acetone. The mixture was stirred for 1 hour, the precipitate was filtered and washed with acetone to yield 1440 mg of the title compound.

5 The paclitaxel content was 2.75% w/w%

Example 6

Copolymer of 1-methacryloylamino -2-hydroxypropane, 1-(methacryloyl-glycyl-phenylanyl-leucyl-glycyl)amino-2-hydroxypropane and 2'-(methacryloyl-glycyl-phenylalanyl-leucyl-glycyl-β-alanyl)paclitaxel.

To a solution of 620 mg of copolymer of 1-methacrylamino-2-hydroxypropane and N-(methylencarbonyl-Phe-Leu-Gly-4-nitro- phenoxy)methacrylamide in 6 ml of anhydrous dimethyl-formamide were added 62 mg of 2'-(β-alanyl)paclitaxel, prepared according to N.F. Magri *et al*, J Nat. Products 51 298-306, 1988, and 10 mg of dimethylamino pyridine. The yellow solution was stirred for 5 hours at room temperature under anhydrous conditions.

20 Then 2-hydroxypropylamine (0.1 ml) was added and the whole was stirred for 30 minutes.

The reaction solution was quenched with 0,15 ml of glacial acetic acid, concentrated under vacuum to a small volume and poured in 150 ml of acetone. The mixure was stirred for 1 hour, the precipitate was filtered and washed with acetone to yield 5.85 mg of the title compound.

The paclitaxel content was 4% w/w%

- 20 -

Example 7

2',7-di(carbobenzyloxy- $\beta$ -alanyl)paclitaxel

To a solution of 200 mg of paclitaxel in 15 ml of acetonitrile were added 400 mg of N,N'-dicyclohexylcarbodiimide, 200 mg of carbobenzyloxy- $\beta$ -alanine and 60 mg of dimethylamino-pyridine. The reaction mixture was stirred for 20 hours, the precipitate was filtered and the solvent evaporated under vacuum to dryness.

10 The residue was chromatographed on silica gel with ethyl acetate-hexane 1:1 as eluant, affording 300 mg of the title compound.

FAB-MS: m/z 1264 M+H]<sup>+</sup>, 1204, 1130, 1070

- 21 -

Example 8

7-(carbobenzyloxy- $\beta$ alanyl)paclitaxel

To a solution of 171 mg of 2'7-di(cARBObENzyLOxy- $\beta$ -alanyl)paclitaxel in 60 ml of methanol, were added 30 mg of sodium bicarbonate and 7 ml of water. The reaction mixture was stirred for 3 hours at room temperature.

5 The methanol was evaporated and the product extracted with ethylacetate.

The solvent was evaporated under vacuum to dryness, 10 affording 134 mg of the title compound.

Example 9

7-( $\beta$ alanyl)paclitaxel

To a solution of 135 mg of 7-(carbobenzyloxy- $\beta$ alanyl)paclitaxel in 20 ml of methanol and 13 ml of 15 formic acid, was added 200 mg of Pd/C 5%. The reaction mixture was stirred for 6 hours at room temperature. The catalyst was filtered, washed with methanol and the solvents were evaporated to dryness under vacuum. The residue was dissolved in 8 ml of methanol and 20 precipitated with 150 ml of diethylether, affording 85 mg of the title compound.

FAB-MS: M/z 925, M+H]<sup>+</sup> ; 947, M+Na]<sup>+</sup>

<sup>1</sup>H NMR(400MHz, CDCl<sub>3</sub>):  $\delta$

1.14 (s, 3H, CH<sub>3</sub>-16)

25 1.20 (s, 3H, CH<sub>3</sub>-17)

1.79 (s, 3H, CH<sub>3</sub>-19)

1.85 (s, 3H, CH<sub>3</sub>-18)

- 22 -

2.17 (s, 3H, CH<sub>3</sub>CO-10)  
2.2-2.6 (m, 6H, CH<sub>2</sub>-14+CH<sub>2</sub>-6+OCOCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>)  
2.42 (s, 3H, CH<sub>3</sub>CO-4)  
3.0-3.2 (m, 2H, OCOCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>)  
5 3.90 (d, J=6.8Hz, 1H, 3)  
4.18, 4.31 (two d, J=8.2Hz, 2H, CH<sub>2</sub>-20)  
4.80 (d, J=3.2Hz, 1H, 2')  
4.91 (d, J=8.5Hz, 1H, 5)  
5.62 (dd, J=10.2Hz, J=7.0Hz, 1H, 7)  
10 5.66 (d, J=6.8Hz, 1H, 2)  
5.81 (dd, J=2.9Hz, J=9.1Hz, 1H, 3')  
6.17 (m, 1H, 13)  
6.19 (s, 1H, 10)  
7.3-8.2 (m, 16H, NH-4'+3-Ph)

15 Example 10

Copolymer of 1-methacryloylamino-2-hydroxypropane, 1-(methacryloyl-glycyl-phenylalanyl-leucyl-glycyl)amino-2-hydroxypropane and 7-(methacryloyl-glycyl-phenylalanyl-leucyl-glycyl- $\beta$ -alanyl)paclitaxel.  
20 To a solution of 1500 mg of copolymer of 1-methacryloyl-amino-2-hydroxypropane and N-(methylencarbonyl-Phe-Leu-Gly-4nitrophenoxy)methacrylamide in 13 ml of anhydrous dimethylformamide were added 135 mg of 7-( $\beta$ -alanyl)paclitaxel and 20 mg of dimethylaminopyridine.  
25 The yellow solution was stirred under anhydrous conditions for 5 hours at room temperature.  
Then 2-hydroxypropylamine (0.2 ml) was added, and the

- 23 -

whole was stirred for 30 minutes.

The reaction solution was quenched with 0.3 ml of glacial acetic acid, concentrated under vacuum to a small volume and poured in 250 ml of acetone. The mixture was stirred for 1 hour, the precipitate was filtered and washed with acetone to yield 1520 mg of the title compound.


5 The paclitaxel content was 7.8% w/w%.

- 24 -


CLAIMS

1. A polymer conjugate consisting essentially of: from 90 to 99.9 mol % of units represented by the formula

5




from 0.1 to 5 mol % of units represented by the formula



10

wherein one of  $R_1$  and  $R_2$  is a copolymer residue of the formula




and the other one is hydrogen atom;

15

from 0 to 9.9 mol % of units represented by the formula

- 25 -




wherein R is a phenyl or t-butoxy group, R<sub>3</sub> is H or an acetyl group, A and A<sub>1</sub> which may be the same or different, represent a chemical single bond, an amino acid residue or peptide spacer selected from  $\beta$  Ala, Gly, Phe-Gly, Phe-Phe-, Leu-Gly, Val-Ala, Phe-Ala, Leu-Phe, Leu-Ala, Phe-Leu-Gly, Phe-Phe-Leu, Leu-Leu-Gly, Phe-Tyr-Ala, Phe-Gly-Phe, Phe-Phe-Gly, Phe-Leu-Gly-Phe, Gly-Phe-Leu-Gly-Phe, Gly- $\beta$ Ala, Phe-Gly- $\beta$ Ala, Phe-Phe- $\beta$ Ala, Leu-Gly- $\beta$ Ala, Val-Ala- $\beta$ Ala, Phe-Ala- $\beta$ Ala, Leu-Phe- $\beta$ Ala, Leu-Gly- $\beta$ Ala, Phe-Leu-Gly- $\beta$ Ala, Phe-Phe-Leu  $\beta$ Ala, Leu-Leu-Gly- $\beta$ Ala, Phe-Tyr-Ala- $\beta$ Ala, Phe-Gly-Phe- $\beta$ , Phe-Phe-Gly  $\beta$ Ala, Phe-Leu-Gly-Phe- $\beta$ Ala or Gly-Phe-Leu-Gly-Phe- $\beta$ Ala.


2. A polymer conjugate according to claim 1, in which R represents a phenyl group, R<sub>3</sub> is an acetyl group and A is a Phe-Leu-Gly or Phe-Leu-Gly- $\beta$ Ala residue.
3. A polymer conjugate according claim 1 or 2, which is a copolymer of 1-methacryloylamino-2-hydroxypropane, (methacryloylglycyl-phenylalanylleucylglycyl)3-amino-2-hydroxypropane and 2'-(methacryloylglycylphenylalanyl-leucylglycyl- $\beta$ alanyl) paclitaxel.

- 26 -


4. A process for preparing a polymer conjugate as defined in claim 1, which process comprises reacting a compound of the formula II



5 wherein one of  $A_2$  and  $A_3$  is a chemical bond and the other one is A, and A, R and  $R_3$  are as defined in claim 1, with an activated polymer consisting essentially of from 90 to 99.9 mol % of units represented by formula



10 and from 10 to 0.1 mol % of units represented by the formula



15 wherein  $A_1$  is as defined in claim 1 and then treating the resultant polymer conjugate with 2-hydroxy-propylamine.

5. A process according to claim 4, in which the reaction is carried out in an anhydrous polar solvent at

- 27 -

a temperature of from 15 to 40°C for from 1 to 24 hours, in the presence of an organic or inorganic base.

6. A compound of the formula II as defined in claim 4 wherein A<sub>2</sub> represents di, tri or tetra peptide spacer as defined in claim 1 for A.

7. A process for preparing a compound of the formula II as defined in claim 6, which process comprises reacting a paclitaxel or a paclitaxel analog with desired protected amino acid or peptide in the presence of a condensating reagent or using activated esters and with or without the additional presence of a catalyst and then removing the protecting groups.

8. A compound of formula II as defined in claim 4 wherein A<sub>3</sub> represents  $\beta$ Ala or di, tri or tetra peptide spacer as defined in claim 1 for A.

9. A process for preparing a compound of the formula II as defined in claim 8, which process comprises either (i) protecting or blocking the 2'-hydroxy group of paclitaxel and esterifying the 7-position hydroxyl and then removing the 2'-protecting or blocking group, or (ii) reacting paclitaxel with 2-3 moles of the desired N-protected amino acid to produce 2',7-disubstituted taxol, cleaving the 2'-position amino acid and then deprotecting the 7-position amino acid.

25 10. A pharmaceutical composition comprising, as active ingredient, a polymer conjugate as defined in claim 1, 6 or 8 and a pharmaceutically acceptable diluent or carrier.

## INTERNATIONAL SEARCH REPORT

PCT/EP 93/01433

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)<sup>6</sup>According to International Patent Classification (IPC) or to both National Classification and IPC  
Int.Cl. 5 A61K47/48; C07D305/14

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.Cl. 5	A61K ; C07D

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	US,A,4 097 470 (J. DROBNIK ET AL.) 27 June 1978 cited in the application see claims; example D ----	1-10
X,Y	MAKROMOL. CHEM. vol. 178, 1977, pages 2169 - 2183 J. KOPECEK 'REACTIVE COPOLYMERS OF N-(2HYDROXYPROPYL)METHACRYLAMIDE WITH N-METHACRYLOYLATED DERIVATIVES OF L-LEUCINE AND L-PHENYLALANINE, 1' see page 2171; figures ----	1-10 -/-

<sup>10</sup> Special categories of cited documents :

- <sup>"A"</sup> document defining the general state of the art which is not considered to be of particular relevance
- <sup>"E"</sup> earlier document but published on or after the international filing date
- <sup>"L"</sup> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- <sup>"O"</sup> document referring to an oral disclosure, use, exhibition or other means
- <sup>"P"</sup> document published prior to the international filing date but later than the priority date claimed

- <sup>"T"</sup> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- <sup>"X"</sup> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

- <sup>"Y"</sup> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

- <sup>"&"</sup> document member of the same patent family

## IV. CERTIFICATION

3 Date of the Actual Completion of the International Search  
11 OCTOBER 1993

Date of Mailing of this International Search Report

12.10.93

International Searching Authority  
EUROPEAN PATENT OFFICESignature of Authorized Officer  
BERTE M.J.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	<p>JOURNAL OF CONTROLLED RELEASE      vol. 18, no. 2, February 1992,      pages 123 - 132</p> <p>V. SUBR ET AL. 'POLYMERS CONTAINING      ENZYMATICALLY DEGRADABLE BONDS, XII.      EFFECT OF SPACER STRUCTURE ON THE RATE OF      RELEASE OF DAUNOMYCIN AND ADRIAMYCIN FROM      HMPA COPOLYMER DRUG CARRIERS IN VITRO AND      ANTITUMOUR ACTIVITY MEASURED IN VIVO.'</p> <p>---</p>	1-10
Y	<p>EP,A,0 187 547 (CARLTON MEDICAL PRODUCTS      LTD.)      16 July 1986      see page 9, line 14 - line 21; claims</p> <p>---</p>	1-10
Y	<p>J. MED. CHEM.      vol. 35, 1992,      pages 145 - 151</p> <p>A. E. MATHEW ET AL. 'SYNTHESIS AND      EVALUATION OF SOME WATER-SOLUBLE PRODRUGS      AND DERIVATIVES OF TAXOL WITH ANTITUMOR      ACTIVITY.'</p> <p>cited in the application</p> <p>---</p>	1-10
A	<p>EP,A,0 393 575 (SEARLE &amp; CO.)      24 October 1990      see page 4, line 10 - page 5, line 38      see page 7, line 57; claims</p> <p>---</p>	1-10
Y	<p>JOURNAL OF CONTROLLED RELEASE      vol. 16, 1991,      pages 121 - 136</p> <p>R. DUNCAN ET AL. 'MACROMOLECULAR PRODRUGS      FOR USE IN TARGETED CANCER CHEMOTHERAPY:      MELPHALAN COVALENTLY COUPLED TO HMPA      COPOLYMERS.'</p> <p>see figure 1; table 1</p> <p>---</p>	1-10
A,P	<p>EP,A,0 537 905 (VIRGINIA TECH. INTELLECT.      PROPERTIES INC.)      21 April 1993</p> <p>-----</p>	1-10

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

EP 9301433  
SA 74848

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.

The members are as contained in the European Patent Office EDP file on

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11/10/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-4097470	27-06-78	None		
EP-A-0187547	16-07-86	AU-B- 589587 AU-A- 5183386 CA-A- 1305053 JP-A- 61243026 US-A- 5037883		19-10-89 10-07-86 14-07-92 29-10-86 06-08-91
EP-A-0393575	24-10-90	CA-A- 2014732 JP-A- 2292227		17-10-90 03-12-90
EP-A-0537905	21-04-93	None		